KANCHAN CLARK: Open Payments
NPI 1649230509 · DANVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,129 in 133 payments from 11 companies in 2025. Trend: 2023 $3,362 · 2024 $3,674 · 2025 $3,129
Food & beverage: $3,129
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $422 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $407 |
| Vanda Pharmaceuticals Inc. | 12 | $349 |
| Neurocrine BioSciences, Inc. | 13 | $307 |
| Otsuka America Pharmaceutical, Inc. | 12 | $300 |
| Lundbeck LLC | 16 | $296 |
| ABBVIE INC. | 15 | $291 |
| Janssen Pharmaceuticals, Inc | 10 | $273 |
| E.R. Squibb & Sons, L.L.C. | 11 | $214 |
| Axsome Therapeutics, Inc. | 8 | $205 |
Products named: ABILIFY ASIMTUFII, ARISTADA, CAPLYTA, INGREZZA, VRAYLAR, INVEGA SUSTENNA, FANAPT, COBENFY.
Industry payments across VA — which companies pay providers there.
